(Q39548875)

13 September 2017

title

HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy (English)

1 reference

13 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Christoph Stephan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

12

Annemarie Berger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Maximilian Donath

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Timo Wolf

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Eva Herrmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Markus Bickel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Pavel Khaykin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Siri Göpel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Peter Gute

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Annette Haberl

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Philipp de Leuw

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Gundolf Schüttfort

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

for Frankfurt HIV Cohort Study

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

28 July 2016

1 reference

Medical Microbiology and Immunology

13 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

575-583

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27469377%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00430-016-0469-7

11 June 2020

exact match

0 references

cites work

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Performance of the Abbott RealTime HIV-1 assay versus the roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

The Theil-Sen Estimator with Doubly Censored Data and Applications to Astronomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-016-0469-7

Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load

21 January 2018

1 reference

12 December 2020

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

1 reference

12 December 2020

Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.

1 reference

12 December 2020

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL

1 reference

12 December 2020

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder

1 reference

12 December 2020

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

1 reference

12 December 2020

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials

1 reference

12 December 2020

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

1 reference

12 December 2020